UNICREDIT BANK/CALL/ELI LILLY & CO/1000/0.1/15.01.25 | Market Closed - BOERSE MUENCHEN 03:41:52 2024-06-28 pm EDT | ||
| 5.69 EUR | +4.40% |
|
| Current month | +87.17% | ||
| 1 month | +97.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 5.69 | +4.40% |
| 24-06-27 | 5.45 | +2.83% |
| 24-06-26 | 5.3 | -0.38% |
| 24-06-25 | 5.32 | +5.56% |
| 24-06-24 | 5.04 | +4.78% |
Real-time BOERSE MUENCHEN
Last update June 28, 2024 at 03:41 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HC9AGM |
| ISIN | DE000HC9AGM1 |
| Date issued | 2023-09-18 |
| Strike | 1,000 $ |
| Maturity | 2025-01-15 (199 Days) |
| Parity | 10 : 1 |
| Emission price | 0.93 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.69 € |
|---|---|
| Lowest since issue | 0.36 € |
| Spread | 0.1 € |
| Spread % | 1.78% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Warrants
- Warrant
